{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:37:10Z","timestamp":1793317030729,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018429","name":"IEO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103212","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:22:29Z","timestamp":1789168949000},"page":"103212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications"],"prefix":"10.1016","volume":"150","author":[{"given":"Julian D.","family":"Etessami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Attili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela Trillo","family":"Aliaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cavallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio M.","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Spitaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung Cancer: a Meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"7878","key":"10.1016\/j.ctrv.2026.103212_bb0010","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103212_bb0020","first-page":"377","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Can"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103212_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070923","article-title":"Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung Cancer: differences and similarities with acquired resistance","volume":"11","author":"Santoni-Rugiu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jtho.2023.11.009","article-title":"Partners in Crime: co-occurring genetic alterations in EGFR-mutant NSCLC","volume":"19","author":"Le","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103212_bb0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line Osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103212_bb0040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103212_bb0045","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103212_bb0050","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103212_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.06.014","article-title":"Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"111","author":"Labb\u00e9","year":"2017","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103212_bb0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103212_bb0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41419-024-06783-7","article-title":"Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance","volume":"15","author":"Guo","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103212_bb0075","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/cdd.2015.53","article-title":"TP53: an oncogene in disguise","volume":"22","author":"Soussi","year":"2015","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41571-023-00842-2","article-title":"Pharmacological reactivation of p53 in the era of precision anticancer medicine","volume":"21","author":"Tuval","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103212_bb0085","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103212_bb0090","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa073770","article-title":"TP53 mutations and survival in squamous-cell carcinoma of the head and neck","volume":"357","author":"Poeta","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtho.2021.08.764","article-title":"Comprehensive analysis of TP53 and KEAP1 mutations and their impact on survival in localized- and advanced-stage NSCLC","volume":"17","author":"Saleh","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0105","doi-asserted-by":"crossref","first-page":"e205601","DOI":"10.1001\/jamasurg.2020.5601","article-title":"A genomic-pathologic annotated risk model to predict recurrence in early-stage lung adenocarcinoma","volume":"156","author":"Jones","year":"2021","journal-title":"JAMA Surg"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103212_bb0110","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung Cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103212_bb0115","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer","volume":"20","author":"Molina-Vila","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103212_bb0120","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2016.02.002","article-title":"Prognostic and predictive effect of TP53 mutations in patients with non-small cell lung Cancer from adjuvant cisplatin-based therapy randomized trials: a LACE-bio pooled analysis","volume":"11","author":"Ma","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103212_bb0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41388-024-03219-6","article-title":"Breathing new insights into the role of mutant p53 in lung cancer","volume":"44","author":"Chen","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2026.103212_bb0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2016.05.001","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status","volume":"97","author":"Cha","year":"2016","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cllc.2021.08.009","article-title":"PD-L1 expression and comprehensive molecular profiling predict survival in nonsmall cell lung Cancer: a real-world study of a large Chinese cohort","volume":"23","author":"Jin","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103212_bb0140","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cllc.2023.12.004","article-title":"Prognostic impact of TP53 mutations in metastatic nonsquamous non-small-cell lung Cancer","volume":"25","author":"Mathiot","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103212_bb0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2019.04.005","article-title":"Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer","volume":"132","author":"Assoun","year":"2019","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103212_bb0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103212_bb0155","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1878-0261.12727","article-title":"Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy","volume":"14","author":"Chan","year":"2020","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41698-024-00544-7","article-title":"Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients","volume":"8","author":"Vasseur","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103212_bb0165","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103212_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092172","article-title":"Genomic characterization of concurrent alterations in non-small cell lung Cancer (NSCLC) Harboring actionable mutations","volume":"13","author":"Passaro","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103212_bb0175","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jtho.2025.04.010","article-title":"Overall survival in EGFR-mutant advanced NSCLC treated with first-line Osimertinib: a cohort study integrating clinical and biomarker data in the United States","volume":"20","author":"Sabari","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103212_bb0180","doi-asserted-by":"crossref","first-page":"e21013","DOI":"10.1200\/JCO.2023.41.16_suppl.e21013","article-title":"Frequency and patterns of TP53 mutations in lung cancer","volume":"41","author":"Yang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103212_bb0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103212_bb0190","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2009.11.026","article-title":"Mutant p53 drives invasion by promoting integrin recycling","volume":"139","author":"Muller","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2026.103212_bb0195","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12935-019-0910-2","article-title":"p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR\/PI3K\/AKT signaling","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103212_bb0200","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1158\/0008-5472.CAN-06-0772","article-title":"p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction","volume":"66","author":"Tang","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41698-024-00557-2","article-title":"TP53 gain-of-function mutations promote osimertinib resistance via TNF-\u03b1-NF-\u03baB signaling in EGFR-mutated lung cancer","volume":"8","author":"Ibusuki","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0210","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13046-024-03220-7","article-title":"MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC","volume":"43","author":"Liu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103212_bb0215","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1158\/0008-5472.CAN-06-2037","article-title":"p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer","volume":"67","author":"Rho","year":"2007","journal-title":"Cancer Res"},{"issue":"1\u20133","key":"10.1016\/j.ctrv.2026.103212_bb0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2008.10.024","article-title":"An epidermal growth factor inhibitor, gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells","volume":"600","author":"Chang","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103212_bb0225","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1158\/0008-5472.CAN-11-0128","article-title":"p53 modulates acquired resistance to EGFR inhibitors and radiation","volume":"71","author":"Huang","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103212_bb0230","article-title":"Cancer stemness: p53 at the wheel","volume":"10","author":"Ghatak","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103212_bb0235","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41388-018-0454-2","article-title":"Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI","volume":"38","author":"Weng","year":"2019","journal-title":"Oncogene"},{"issue":"26","key":"10.1016\/j.ctrv.2026.103212_bb0240","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","article-title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","article-title":"Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC","volume":"14","author":"Kim","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103212_bb0250","article-title":"Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non-small-cell lung cancer","volume":"2018","author":"Aggarwal","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103212_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105326","article-title":"Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study","volume":"10","author":"Catania","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0260","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","article-title":"Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung Cancer","volume":"19","author":"Stockhammer","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0265","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cllc.2020.11.001","article-title":"Predictive and prognostic potential of TP53 in patients with advanced non-small-cell lung Cancer treated with EGFR-TKI: analysis of a phase III randomized clinical trial (CTONG 0901)","volume":"22","author":"Li","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103212_bb0270","article-title":"The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs","volume":"13","author":"Gu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103212_bb0275","doi-asserted-by":"crossref","first-page":"vi426","DOI":"10.1093\/annonc\/mdw383.32","article-title":"P53 non-disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI","volume":"27","author":"Griesinger","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103212_bb0280","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.2147\/CMAR.S201513","article-title":"Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC","volume":"11","author":"Hou","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103212_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9041047","article-title":"Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung Cancer patients treated with TKIs","volume":"9","author":"Canale","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0290","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cllc.2022.08.007","article-title":"Impact of TP53 mutations on EGFR-tyrosine kinase inhibitor efficacy and potential treatment strategy","volume":"24","author":"Fu","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103212_bb0295","author":"Aisner"},{"key":"10.1016\/j.ctrv.2026.103212_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103929","article-title":"Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors","volume":"184","author":"Ferrara","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"40","key":"10.1016\/j.ctrv.2026.103212_bb0305","doi-asserted-by":"crossref","first-page":"26195","DOI":"10.18632\/oncotarget.25490","article-title":"Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment","volume":"9","author":"Jakobsen","year":"2018","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103212_bb0310","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1002\/cncr.34451","article-title":"Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X\/L861Q\/S768I","volume":"128","author":"Pang","year":"2022","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0315","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00676-2023","article-title":"Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib","volume":"10","author":"Liang","year":"2024","journal-title":"ERJ Open Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103212_bb0320","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.annonc.2022.02.225","article-title":"Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)","volume":"33","author":"Janning","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0325","article-title":"EGFR G719X+S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort","volume":"26","author":"Zhang","year":"2026","journal-title":"BMC Cancer"},{"issue":"26","key":"10.1016\/j.ctrv.2026.103212_bb0330","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.24.00071","article-title":"Neoadjuvant Osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung Cancer: a phase II Multicenter study","volume":"42","author":"Blakely","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0335","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1038\/s41467-021-26806-7","article-title":"Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103212_bb0340","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103212_bb0345","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cllc.2023.02.010","article-title":"RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and clinical outcome","volume":"24","author":"Nishio","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103212_bb0350","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2020.04.004","article-title":"Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors","volume":"145","author":"Cheng","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0355","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-023-10637-4","article-title":"Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study","volume":"23","author":"Sun","year":"2023","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103212_bb0360","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jtho.2024.09.186","article-title":"MA12.06 PAPILLON: TP53 co-mutations, sites of insertion, and ctDNA clearance among patients with EGFR Ex20ins-mutated advanced NSCLC","volume":"19","author":"Goldman","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103212_bb0365","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.21037\/tlcr-23-643","article-title":"Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)","volume":"12","author":"Choi","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103212_bb0370","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103212_bb0375","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with Amivantamab-Lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103212_bb0380","doi-asserted-by":"crossref","first-page":"S1245","DOI":"10.1016\/j.annonc.2024.08.2297","article-title":"LBA55 mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: an early analysis from the phase III MARIPOSA study","volume":"35","author":"Besse","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103212_bb0385","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1200\/JCO.2025.43.16_suppl.8639","article-title":"Amivantamab plus chemotherapy vs chemotherapy in EGFR -mutant advanced NSCLC after disease progression on osimertinib: outcomes by osimertinib resistance mechanisms in MARIPOSA-2","volume":"43","author":"Califano","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103212_bb0390","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103212_bb0395","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","article-title":"TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma","volume":"24","author":"Biton","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103212_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102990","article-title":"Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma","volume":"60","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103212_bb0405","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"10066","key":"10.1016\/j.ctrv.2026.103212_bb0410","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"10027","key":"10.1016\/j.ctrv.2026.103212_bb0415","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103212_bb0420","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103212_bb0425","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib plus durvalumab versus Osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103212_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143560","article-title":"The development of p53-targeted therapies for human cancers","volume":"15","author":"Lu","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103212_bb0435","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1200\/JCO.2024.42.16_suppl.8565","article-title":"Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations","volume":"42","author":"Chen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103212_bb0440","article-title":"Aumolertinib with carboplatin\u2013pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): an open-label, multicenter, randomized phase 3 study","volume":"76","author":"Duan","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103212_bb0445","article-title":"Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2026.103212_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106309","article-title":"2O Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)","volume":"11","author":"Yang","year":"2026","journal-title":"ESMO Open"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:09Z","timestamp":1793316549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722600126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":90,"alternative-id":["S030573722600126X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103212","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103212"}}